Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Bob Rudd who wrote (595)	5/4/1998 10:22:00 PM
From: Andreas Helke	Read Replies (2) \| Respond to of 2135

I think Entremed has not yet licensed endostatin to a pharma company. If ENMD stock stays up they can raise the necessary development money by selling stock instead of going into a partnership with a pharma company. This may be a decent strategy with a drug candidate as promising as endostatin. They will definitely not have any problem to sell all endostatin that they can produce. This is quite a contrast to the average biotech drug where an established pharma sales force is almost an requirement to actually sell the stuff. Does anyone know if the basic mechanism of endostatin action is known? The only thing that I know from a reliable source (paper in a peer reviewed scientific journal) is that endostatin is great and probably unrivaled in its ability to shrink and suppress the growth of mouse tumors. Andreas